PharmEasy Parent API Holdings Raises ₹1,700 Crore, Pledges 61% Stake in Thyrocare as Collateral

API Holdings Ltd., the parent company of PharmEasy, has successfully raised ₹1,700 crore through the issuance of non-convertible debentures (NCDs), marking a significant step in the company’s financial restructuring efforts. The proceeds from this issuance will primarily be used to repay and refinance existing debt obligations, thereby improving liquidity and strengthening the company’s balance sheet.

As part of the financing arrangement, Docon Technologies Pvt. Ltd., a wholly owned subsidiary of API Holdings and the promoter entity of Thyrocare Technologies Ltd., has pledged approximately 3.23 crore shares, representing around 61% of Thyrocare’stotal equity, as collateral to secure the NCDs.

This move is a continuation of API Holdings’ strategy to manage debt effectively while leveraging its strong asset base. The company had previously pledged about 71% of Thyrocare’s shares for an earlier funding round, and this new structure represents a reduction in pledged shares, reflecting improved financial flexibility.

The fundraising comes at a time when the company is focusing on stabilizing operations and ensuring sustainable growth in the competitive healthcare and health-tech space. PharmEasy, one of India’s largest online healthcare platforms, continues to expand its reach in diagnostics, telemedicine, and pharmacy services, while Thyrocare remains a key contributor through its nationwide diagnostic network.

This development highlights API Holdings’ commitment to long-term financial discipline and growth, as it works to build a robust and scalable healthcare ecosystem in India.